Status:
UNKNOWN
TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS
Lead Sponsor:
Institut Paoli-Calmettes
Collaborating Sponsors:
Hospital Clínico Universitario de Valencia
Conditions:
Hematologic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Torque Teno Virus (TTV) prevalence in the general population is very high (\>90%) and has not been consistently confirmed to cause any disease. Kidney transplant studies seem to indicate that an eleva...
Detailed Description
Torque Teno Virus (TTV) is the prototype of the Anelloviridae family-single chain and circular viruses. These viruses form about 70% of the human virome. TTV prevalence in the general population is ve...
Eligibility Criteria
Inclusion
- Adult patients (\>=18 years).
- Patient going to be treated by CAR-T Cell therapy
- Able to comply with the protocol.
- Written informed consent.
- Patient affiliated to the national "Social Security" regimen or beneficiary of this regimen
Exclusion
- Pregnancy/breast feeding.
- Patient considered socially or psychologically unable to comply with the treatment and the required medical follow-up.
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04822974
Start Date
May 1 2021
End Date
September 1 2022
Last Update
March 30 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.